Cendakimab fell short of the bar. The antibody hits IL-13, one of the interleukins targeted by Regeneron and Sanofi’s ...

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era ...

Novartis, Eli Lilly and more put on their deal-making caps, Bristol Myers Squibb targets $2 billion in savings through 2027, sales continue to soar for Lilly and Novo Nordisk’s GLP-1s and Regeneron ...

Mucinex knocked Vicks off the top spot for monthly TV ad impressions as pharma brands generated significant coverage from ...

That's less than the cost of other biologics for severe asthma like GlaxoSmithKline's IL-5 inhibitor Nucala (mepolizumab) and Sanofi/Regeneron's IL-4 and IL-13 inhibitor Dupixent (dupilumab ...

It’s likely that patients with the most severe disease will be the first to receive Dupixent in the UK and other EU markets. England’s cost effectiveness watchdog NICE is in the early stages ...

We think the strategy to find more effective combination therapies in hematology and build a larger oncology and dermatology portfolio is solid, although we're waiting for key data before assuming the ...

CFRA analysts increased their price target on shares of Sanofi (SAN:FP) (NASDAQ: NASDAQ:SNY) to EUR6.50, up from the previous EUR5.00, while keeping a Buy rating on the stock. Currently trading at $54 ...

Cost accounting is a process that measures all of the expenses associated with running a business, including both fixed and variable costs. The results help management make decisions that optimize ...

Cost accounting is a process that involves recording, analyzing, and reporting a company's expenses in detail. Unlike financial accounting, cost accounting is an internal process used only by ...